Merck Closes Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering

Advances Merck’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing

06-Aug-2024 - Merck announced the closing of the transaction to acquire Mirus Bio for approximately US$600million (around €550million), following regulatory clearances and the fulfillment of other customary closing conditions. The acquisition is a strategic step towards Merck's ambition to offer solutions ...

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million

"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

24-May-2024 - Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$600million (around €550million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's ...

Merck sells its Flow Cytometry unit for €62.5 million

19-Oct-2018 - Merck announced the signing of a definitive agreement to sell its Flow Cytometry unit to Luminex Corporation for €62.5 million. The closing of the transaction, expected by the end of 2018, is subject to customary closing conditions. Upon completion of the transaction, Luminex will own the flow ...

Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry

23-Sep-2014 - Merck and Sigma-Aldrich announced that they have entered into a definitive agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion (€13.1 billion), establishing one of the leading players in the $130 billion global life science industry. Merck will acquire all of the outstanding ...

Chemicon International to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology from WARF

27-Jul-2005 - Serologicals Corporation announced that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, and the Wisconsin Alumni Research Foundation (WARF) have signed a license to commercialize research products derived from patented human embryonic stem (ES) cell technology. ...